Clinical Trial Update: Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

BeiGene's BGB-11417 is being studied in a Phase 2 trial for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The study is curr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• BGB-11417

Snippet

Sponsor: BeiGene | Conditions: Leukemia, Lymphoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING